| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
58,625,000 |
| Market
Cap: |
1.76(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.72 - $37.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
98,505 |
119,208 |
124,343 |
450,780 |
| Total Sell Value |
$3,345,846 |
$3,929,526 |
$4,091,741 |
$15,155,681 |
| Total People Sold |
1 |
5 |
5 |
6 |
| Total Sell Transactions |
6 |
10 |
11 |
37 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
9,517 |
|
- |
|
| Hudson Frederick M. |
Director |
– • – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,882 |
34,867 |
|
- |
|
| Siebert John M |
Director |
– • – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,882 |
84,057 |
|
- |
|
| Newhall Charles W III |
Director |
– • – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,882 |
112,132 |
|
- |
|
| Barlow Carrolee |
Director |
– • – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,882 |
13,315 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
1,341 |
|
- |
|
| Gemayel Georges |
Director |
– • – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,882 |
13,315 |
|
- |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
90,323 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
3,247 |
|
- |
|
| Rubin Jonathan |
SVP, Chief Medical Officer |
• – – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
1,500 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2023-02-16 |
4 |
D |
$38.74 |
$29,171 |
D/D |
(753) |
8,191 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
8,944 |
|
- |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
88,720 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,750) |
1,038,950 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
813,022 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-03 |
4 |
S |
$42.02 |
$8,404 |
D/D |
(200) |
804,272 |
|
19% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-03 |
4 |
OE |
$9.56 |
$3,155 |
D/D |
330 |
804,472 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-02 |
4 |
AS |
$42.06 |
$569,088 |
D/D |
(13,532) |
804,142 |
|
-19% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-02 |
4 |
OE |
$9.56 |
$215,243 |
D/D |
22,515 |
817,674 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-01 |
4 |
AS |
$42.01 |
$12,602 |
D/D |
(300) |
795,159 |
|
-18% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-02-01 |
4 |
OE |
$9.56 |
$4,761 |
D/D |
498 |
795,459 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-01-31 |
4 |
AS |
$42.01 |
$41,002 |
D/D |
(976) |
794,961 |
|
-15% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-01-31 |
4 |
OE |
$9.56 |
$15,487 |
D/D |
1,620 |
795,937 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-01-18 |
4 |
AS |
$40.40 |
$199,394 |
D/D |
(4,936) |
794,317 |
|
-16% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-01-18 |
4 |
OE |
$9.56 |
$77,245 |
D/D |
8,080 |
799,253 |
|
- |
|
345 Records found
|
|
Page 4 of 14 |
|
|
0.76 (2.59%) 
